Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 9985 to 9996 of 12569 entries
Sorted by: Best Match Show Resources per page
[No title available]

Frontiers in pharmacology

Yu P, Li Y, Fu W, Li X, Liu Y, Wang Y, Yu X, Xu H, Sui D.
PMID: 33628178
Front Pharmacol. 2021 Jan 15;11:607813. doi: 10.3389/fphar.2020.607813. eCollection 2020.

At present, many patients who undergo reperfusion immediately after percutaneous coronary intervention will undergo microvascular obstruction and reduction in myocardial blood flow. This phenomenon is called "no-reflow (NR)," and there is still no effective therapy for NR. Studies showed

Cite
Yu P, Li Y, Fu W, et al. . Front Pharmacol. 2021;11:607813doi: 10.3389/fphar.2020.607813.
Yu, P., Li, Y., Fu, W., Li, X., Liu, Y., Wang, Y., Yu, X., Xu, H., & Sui, D. (2020). . Frontiers in pharmacology, 11607813. https://doi.org/10.3389/fphar.2020.607813
Yu, Ping, et al. "." Frontiers in pharmacology vol. 11 (2020): 607813. doi: https://doi.org/10.3389/fphar.2020.607813
Yu P, Li Y, Fu W, Li X, Liu Y, Wang Y, Yu X, Xu H, Sui D. . Front Pharmacol. 2021 Jan 15;11:607813. doi: 10.3389/fphar.2020.607813. eCollection 2020. PMID: 33628178; PMCID: PMC7898550.
Copy Download .nbib Format: NLM
Comparison of Adverse Kidney Outcomes With Empagliflozin and Linagliptin Use in Patients With Type 2 Diabetic Patients in a Real-World Setting.

Frontiers in pharmacology

Lee YT, Hsu CN, Fu CM, Wang SW, Huang CC, Li LC.
PMID: 34992535
Front Pharmacol. 2021 Dec 21;12:781379. doi: 10.3389/fphar.2021.781379. eCollection 2021.

No abstract available.

Cite
Lee YT, Hsu CN, Fu CM, et al. Comparison of Adverse Kidney Outcomes With Empagliflozin and Linagliptin Use in Patients With Type 2 Diabetic Patients in a Real-World Setting. Front Pharmacol. 2021;12:781379doi: 10.3389/fphar.2021.781379.
Lee, Y. T., Hsu, C. N., Fu, C. M., Wang, S. W., Huang, C. C., & Li, L. C. (2021). Comparison of Adverse Kidney Outcomes With Empagliflozin and Linagliptin Use in Patients With Type 2 Diabetic Patients in a Real-World Setting. Frontiers in pharmacology, 12781379. https://doi.org/10.3389/fphar.2021.781379
Lee, Yueh-Ting, et al. "Comparison of Adverse Kidney Outcomes With Empagliflozin and Linagliptin Use in Patients With Type 2 Diabetic Patients in a Real-World Setting." Frontiers in pharmacology vol. 12 (2021): 781379. doi: https://doi.org/10.3389/fphar.2021.781379
Lee YT, Hsu CN, Fu CM, Wang SW, Huang CC, Li LC. Comparison of Adverse Kidney Outcomes With Empagliflozin and Linagliptin Use in Patients With Type 2 Diabetic Patients in a Real-World Setting. Front Pharmacol. 2021 Dec 21;12:781379. doi: 10.3389/fphar.2021.781379. eCollection 2021. PMID: 34992535; PMCID: PMC8724779.
Copy Download .nbib Format: NLM
The Development and Validation of a Generic Instrument, QoDoS, for Assessing the Quality of Decision Making.

Frontiers in pharmacology

Donelan R, Walker S, Salek S.
PMID: 27468267
Front Pharmacol. 2016 Jul 13;7:180. doi: 10.3389/fphar.2016.00180. eCollection 2016.

INTRODUCTION: The impact of decision-making during the development and the regulatory review of medicines greatly influences the delivery of new medicinal products. Currently, there is no generic instrument that can be used to assess the quality of decision-making. This...

Cite
Donelan R, Walker S, Salek S. The Development and Validation of a Generic Instrument, QoDoS, for Assessing the Quality of Decision Making. Front Pharmacol. 2016;7:180doi: 10.3389/fphar.2016.00180.
Donelan, R., Walker, S., & Salek, S. (2016). The Development and Validation of a Generic Instrument, QoDoS, for Assessing the Quality of Decision Making. Frontiers in pharmacology, 7180. https://doi.org/10.3389/fphar.2016.00180
Donelan, Ronan, et al. "The Development and Validation of a Generic Instrument, QoDoS, for Assessing the Quality of Decision Making." Frontiers in pharmacology vol. 7 (2016): 180. doi: https://doi.org/10.3389/fphar.2016.00180
Donelan R, Walker S, Salek S. The Development and Validation of a Generic Instrument, QoDoS, for Assessing the Quality of Decision Making. Front Pharmacol. 2016 Jul 13;7:180. doi: 10.3389/fphar.2016.00180. eCollection 2016. PMID: 27468267; PMCID: PMC4942854.
Copy Download .nbib Format: NLM
The Systemic Changes to Improve Efficiency in Polish Primary Health Care.

Frontiers in pharmacology

Holecki T, Romaniuk P, Woźniak-Holecka J.
PMID: 27468269
Front Pharmacol. 2016 Jul 13;7:209. doi: 10.3389/fphar.2016.00209. eCollection 2016.

Primary health care is an important part of any health care system. In highly developed countries it secures the population's most elementary health needs, with particular emphasis on preventive care and early intervention. Polish PHC model is currently undergoing...

Cite
Holecki T, Romaniuk P, Woźniak-Holecka J. The Systemic Changes to Improve Efficiency in Polish Primary Health Care. Front Pharmacol. 2016;7:209doi: 10.3389/fphar.2016.00209.
Holecki, T., Romaniuk, P., & Woźniak-Holecka, J. (2016). The Systemic Changes to Improve Efficiency in Polish Primary Health Care. Frontiers in pharmacology, 7209. https://doi.org/10.3389/fphar.2016.00209
Holecki, Tomasz, et al. "The Systemic Changes to Improve Efficiency in Polish Primary Health Care." Frontiers in pharmacology vol. 7 (2016): 209. doi: https://doi.org/10.3389/fphar.2016.00209
Holecki T, Romaniuk P, Woźniak-Holecka J. The Systemic Changes to Improve Efficiency in Polish Primary Health Care. Front Pharmacol. 2016 Jul 13;7:209. doi: 10.3389/fphar.2016.00209. eCollection 2016. PMID: 27468269; PMCID: PMC4943038.
Copy Download .nbib Format: NLM
Commentary: Comparison of historical medical spending patterns among the BRICS and G7.

Frontiers in pharmacology

Buttigieg SC, Grima S, Camilleri C.
PMID: 27469453
Front Pharmacol. 2016 Jul 14;7:213. doi: 10.3389/fphar.2016.00213. eCollection 2016.

No abstract available.

Cite
Buttigieg SC, Grima S, Camilleri C. Commentary: Comparison of historical medical spending patterns among the BRICS and G7. Front Pharmacol. 2016;7:213doi: 10.3389/fphar.2016.00213.
Buttigieg, S. C., Grima, S., & Camilleri, C. (2016). Commentary: Comparison of historical medical spending patterns among the BRICS and G7. Frontiers in pharmacology, 7213. https://doi.org/10.3389/fphar.2016.00213
Buttigieg, Sandra C, et al. "Commentary: Comparison of historical medical spending patterns among the BRICS and G7." Frontiers in pharmacology vol. 7 (2016): 213. doi: https://doi.org/10.3389/fphar.2016.00213
Buttigieg SC, Grima S, Camilleri C. Commentary: Comparison of historical medical spending patterns among the BRICS and G7. Front Pharmacol. 2016 Jul 14;7:213. doi: 10.3389/fphar.2016.00213. eCollection 2016. PMID: 27469453; PMCID: PMC4943930.
Copy Download .nbib Format: NLM
Pancreatic β Cell Mass Death.

Frontiers in pharmacology

Marrif HI, Al-Sunousi SI.
PMID: 27092078
Front Pharmacol. 2016 Apr 06;7:83. doi: 10.3389/fphar.2016.00083. eCollection 2016.

Type two diabetes (T2D) is a challenging metabolic disorder for which a cure has not yet been found. Its etiology is associated with several phenomena, including significant loss of insulin-producing, beta cell (β cell) mass via progressive programmed cell...

Cite
Marrif HI, Al-Sunousi SI. Pancreatic β Cell Mass Death. Front Pharmacol. 2016;7:83doi: 10.3389/fphar.2016.00083.
Marrif, H. I., & Al-Sunousi, S. I. (2016). Pancreatic β Cell Mass Death. Frontiers in pharmacology, 783. https://doi.org/10.3389/fphar.2016.00083
Marrif, Husnia I, and Al-Sunousi, Salma I. "Pancreatic β Cell Mass Death." Frontiers in pharmacology vol. 7 (2016): 83. doi: https://doi.org/10.3389/fphar.2016.00083
Marrif HI, Al-Sunousi SI. Pancreatic β Cell Mass Death. Front Pharmacol. 2016 Apr 06;7:83. doi: 10.3389/fphar.2016.00083. eCollection 2016. PMID: 27092078; PMCID: PMC4821858.
Copy Download .nbib Format: NLM
Activation of Sterol Regulatory Element Binding Factors by Fenofibrate and Gemfibrozil Stimulates Myelination in Zebrafish.

Frontiers in pharmacology

Ashikawa Y, Nishimura Y, Okabe S, Sasagawa S, Murakami S, Yuge M, Kawaguchi K, Kawase R, Tanaka T.
PMID: 27462272
Front Pharmacol. 2016 Jul 11;7:206. doi: 10.3389/fphar.2016.00206. eCollection 2016.

Oligodendrocytes are major myelin-producing cells and play essential roles in the function of a healthy nervous system. However, they are also one of the most vulnerable neural cell types in the central nervous system (CNS), and myelin abnormalities in...

Cite
Ashikawa Y, Nishimura Y, Okabe S, et al. Activation of Sterol Regulatory Element Binding Factors by Fenofibrate and Gemfibrozil Stimulates Myelination in Zebrafish. Front Pharmacol. 2016;7:206doi: 10.3389/fphar.2016.00206.
Ashikawa, Y., Nishimura, Y., Okabe, S., Sasagawa, S., Murakami, S., Yuge, M., Kawaguchi, K., Kawase, R., & Tanaka, T. (2016). Activation of Sterol Regulatory Element Binding Factors by Fenofibrate and Gemfibrozil Stimulates Myelination in Zebrafish. Frontiers in pharmacology, 7206. https://doi.org/10.3389/fphar.2016.00206
Ashikawa, Yoshifumi, et al. "Activation of Sterol Regulatory Element Binding Factors by Fenofibrate and Gemfibrozil Stimulates Myelination in Zebrafish." Frontiers in pharmacology vol. 7 (2016): 206. doi: https://doi.org/10.3389/fphar.2016.00206
Ashikawa Y, Nishimura Y, Okabe S, Sasagawa S, Murakami S, Yuge M, Kawaguchi K, Kawase R, Tanaka T. Activation of Sterol Regulatory Element Binding Factors by Fenofibrate and Gemfibrozil Stimulates Myelination in Zebrafish. Front Pharmacol. 2016 Jul 11;7:206. doi: 10.3389/fphar.2016.00206. eCollection 2016. PMID: 27462272; PMCID: PMC4939524.
Copy Download .nbib Format: NLM
Preclinical Pharmacokinetics, Tissue Distribution, and Plasma Protein Binding of Sodium (±)-5-Bromo-2-(α-Hydroxypentyl) Benzoate (BZP), an Innovative Potent Anti-ischemic Stroke Agent.

Frontiers in pharmacology

Tian X, Li HM, Wei JY, Liu BJ, Zhang YH, Wang GJ, Chang JB, Qiao HL.
PMID: 27588003
Front Pharmacol. 2016 Aug 18;7:255. doi: 10.3389/fphar.2016.00255. eCollection 2016.

Sodium (±)-5-bromo-2-(α-hydroxypentyl) benzoate (BZP) is a potential cardiovascular drug and exerts potent neuroprotective effect against transient and long-term ischemic stroke in rats. BZP could convert into 3-butyl-6-bromo-1(3H)-isobenzofuranone (Br-NBP) in vitro and in vivo. However, the pharmacokinetic profiles of BZP...

Cite
Tian X, Li HM, Wei JY, et al. Preclinical Pharmacokinetics, Tissue Distribution, and Plasma Protein Binding of Sodium (±)-5-Bromo-2-(α-Hydroxypentyl) Benzoate (BZP), an Innovative Potent Anti-ischemic Stroke Agent. Front Pharmacol. 2016;7:255doi: 10.3389/fphar.2016.00255.
Tian, X., Li, H. M., Wei, J. Y., Liu, B. J., Zhang, Y. H., Wang, G. J., Chang, J. B., & Qiao, H. L. (2016). Preclinical Pharmacokinetics, Tissue Distribution, and Plasma Protein Binding of Sodium (±)-5-Bromo-2-(α-Hydroxypentyl) Benzoate (BZP), an Innovative Potent Anti-ischemic Stroke Agent. Frontiers in pharmacology, 7255. https://doi.org/10.3389/fphar.2016.00255
Tian, Xin, et al. "Preclinical Pharmacokinetics, Tissue Distribution, and Plasma Protein Binding of Sodium (±)-5-Bromo-2-(α-Hydroxypentyl) Benzoate (BZP), an Innovative Potent Anti-ischemic Stroke Agent." Frontiers in pharmacology vol. 7 (2016): 255. doi: https://doi.org/10.3389/fphar.2016.00255
Tian X, Li HM, Wei JY, Liu BJ, Zhang YH, Wang GJ, Chang JB, Qiao HL. Preclinical Pharmacokinetics, Tissue Distribution, and Plasma Protein Binding of Sodium (±)-5-Bromo-2-(α-Hydroxypentyl) Benzoate (BZP), an Innovative Potent Anti-ischemic Stroke Agent. Front Pharmacol. 2016 Aug 18;7:255. doi: 10.3389/fphar.2016.00255. eCollection 2016. PMID: 27588003; PMCID: PMC4990024.
Copy Download .nbib Format: NLM
Morphine use in cancer surgery.

Frontiers in pharmacology

Afsharimani B, Cabot PJ, Parat MO.
PMID: 21852973
Front Pharmacol. 2011 Aug 08;2:46. doi: 10.3389/fphar.2011.00046. eCollection 2011.

Morphine is the core of perioperative pain management. However, when it comes to cancer surgery the possibility that this drug might affect tumor recurrence and metastasis has raised concerns. The results of two recent retrospective clinical trials indicated that...

Cite
Afsharimani B, Cabot PJ, Parat MO. Morphine use in cancer surgery. Front Pharmacol. 2011;2:46doi: 10.3389/fphar.2011.00046.
Afsharimani, B., Cabot, P. J., & Parat, M. O. (2011). Morphine use in cancer surgery. Frontiers in pharmacology, 246. https://doi.org/10.3389/fphar.2011.00046
Afsharimani, Banafsheh, et al. "Morphine use in cancer surgery." Frontiers in pharmacology vol. 2 (2011): 46. doi: https://doi.org/10.3389/fphar.2011.00046
Afsharimani B, Cabot PJ, Parat MO. Morphine use in cancer surgery. Front Pharmacol. 2011 Aug 08;2:46. doi: 10.3389/fphar.2011.00046. eCollection 2011. PMID: 21852973; PMCID: PMC3151591.
Copy Download .nbib Format: NLM
Strategies for developing novel therapeutics for sensorineural hearing loss.

Frontiers in pharmacology

Nakagawa T.
PMID: 25278894
Front Pharmacol. 2014 Sep 16;5:206. doi: 10.3389/fphar.2014.00206. eCollection 2014.

Sensorineural hearing loss (SNHL) is a common disability in the world; however, at present, options for the pharmacological treatment of SNHL are very limited. Previous studies involving human temporal bone analyses have revealed that the degeneration of the cochlea...

Cite
Nakagawa T. Strategies for developing novel therapeutics for sensorineural hearing loss. Front Pharmacol. 2014;5:206doi: 10.3389/fphar.2014.00206.
Nakagawa, T. (2014). Strategies for developing novel therapeutics for sensorineural hearing loss. Frontiers in pharmacology, 5206. https://doi.org/10.3389/fphar.2014.00206
Nakagawa, Takayuki. "Strategies for developing novel therapeutics for sensorineural hearing loss." Frontiers in pharmacology vol. 5 (2014): 206. doi: https://doi.org/10.3389/fphar.2014.00206
Nakagawa T. Strategies for developing novel therapeutics for sensorineural hearing loss. Front Pharmacol. 2014 Sep 16;5:206. doi: 10.3389/fphar.2014.00206. eCollection 2014. PMID: 25278894; PMCID: PMC4165348.
Copy Download .nbib Format: NLM
Calcium and IP3 dynamics in cardiac myocytes: experimental and computational perspectives and approaches.

Frontiers in pharmacology

Hohendanner F, McCulloch AD, Blatter LA, Michailova AP.
PMID: 24639654
Front Pharmacol. 2014 Mar 06;5:35. doi: 10.3389/fphar.2014.00035. eCollection 2014.

Calcium plays a crucial role in excitation-contraction coupling (ECC), but it is also a pivotal second messenger activating Ca(2+)-dependent transcription factors in a process termed excitation-transcription coupling (ETC). Evidence accumulated over the past decade indicates a pivotal role of...

Cite
Hohendanner F, McCulloch AD, Blatter LA, et al. Calcium and IP3 dynamics in cardiac myocytes: experimental and computational perspectives and approaches. Front Pharmacol. 2014;5:35doi: 10.3389/fphar.2014.00035.
Hohendanner, F., McCulloch, A. D., Blatter, L. A., & Michailova, A. P. (2014). Calcium and IP3 dynamics in cardiac myocytes: experimental and computational perspectives and approaches. Frontiers in pharmacology, 535. https://doi.org/10.3389/fphar.2014.00035
Hohendanner, Felix, et al. "Calcium and IP3 dynamics in cardiac myocytes: experimental and computational perspectives and approaches." Frontiers in pharmacology vol. 5 (2014): 35. doi: https://doi.org/10.3389/fphar.2014.00035
Hohendanner F, McCulloch AD, Blatter LA, Michailova AP. Calcium and IP3 dynamics in cardiac myocytes: experimental and computational perspectives and approaches. Front Pharmacol. 2014 Mar 06;5:35. doi: 10.3389/fphar.2014.00035. eCollection 2014. PMID: 24639654; PMCID: PMC3944219.
Copy Download .nbib Format: NLM
Physiological mechanisms of vascular response induced by shear stress and effect of exercise in systemic and placental circulation.

Frontiers in pharmacology

Rodríguez I, González M.
PMID: 25278895
Front Pharmacol. 2014 Sep 16;5:209. doi: 10.3389/fphar.2014.00209. eCollection 2014.

Physiological vascular function regulation is essential for cardiovascular health and depends on adequate control of molecular mechanisms triggered by endothelial cells in response to mechanical and chemical stimuli induced by blood flow. Endothelial dysfunction is one of the main...

Cite
Rodríguez I, González M. Physiological mechanisms of vascular response induced by shear stress and effect of exercise in systemic and placental circulation. Front Pharmacol. 2014;5:209doi: 10.3389/fphar.2014.00209.
Rodríguez, I., & González, M. (2014). Physiological mechanisms of vascular response induced by shear stress and effect of exercise in systemic and placental circulation. Frontiers in pharmacology, 5209. https://doi.org/10.3389/fphar.2014.00209
Rodríguez, Iván, and González, Marcelo. "Physiological mechanisms of vascular response induced by shear stress and effect of exercise in systemic and placental circulation." Frontiers in pharmacology vol. 5 (2014): 209. doi: https://doi.org/10.3389/fphar.2014.00209
Rodríguez I, González M. Physiological mechanisms of vascular response induced by shear stress and effect of exercise in systemic and placental circulation. Front Pharmacol. 2014 Sep 16;5:209. doi: 10.3389/fphar.2014.00209. eCollection 2014. PMID: 25278895; PMCID: PMC4165280.
Copy Download .nbib Format: NLM
Showing 9985 to 9996 of 12569 entries